Work

Abstract CT093: Axitinib in combination with pembrolizumab (AXI+PEMBRO) in patients (pts) with advanced renal cell carcinoma (aRCC): Analysis of immune-related biomarkers

Year: 2019

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2019-ct093

Authors: Michael Atkins, Jean-Francois Martini, Elizabeth Plimack, David McDermott, Igor Puzanov, Mayer Fishman, Daniel Cho, Ulka Vaishampayan, Brad Rosbrook, Kathrine Fernandez, Jamal Tarazi, Saby George, Toni Choueiri

Institutions: Georgetown Lombardi Comprehensive Cancer Center, Fox Chase Cancer Center, Beth Israel Deaconess Medical Center, Roswell Park Comprehensive Cancer Center, Moffitt Cancer Center, NYU Langone Health, New York University, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Pfizer (United States), Dana-Farber Cancer Institute

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2953724760

Cites:

Cited by:

Related to: 10